《中国心力衰竭诊断和治疗指南2024》解读

许顶立; 宋霖

doi:10.13201/j.issn.1001-1439.2024.06.002

《中国心力衰竭诊断和治疗指南2024》解读

许顶立^1, ,,
宋霖¹

- 南方医科大学南方医院心内科(广州，510515)

详细信息

通讯作者: 许顶立，E-mail：dinglixu@smu.edu.cn

中图分类号: R541.6

收稿日期: 2024-04-16

刊出日期: 2024-06-13

Interpretation of Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024

XU Dingli^1, ,,
SONG Lin¹

- Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China

More Information

Corresponding author: XU Dingli, E-mail: dinglixu@smu.edu.cn

Received Date: 16 April 2024

Publish Date: 13 June 2024

摘要

摘要: 《中国心力衰竭诊断和治疗指南2024》中心力衰竭(心衰)的分类新增了左室射血分数改善的心衰，更新了慢性心衰的诊断流程和推荐等级，强调“新四联”治疗的基石地位。新增了终末期心衰的定义标准，更新了心衰常见合并症的处理。
- 心力衰竭 /
- 诊断流程 /
- 推荐等级 /
- 指南解读
Abstract: "China Heart Failure Diagnosis and Treatment Guidelines 2024" added heart failure with improved left ventricular ejection fraction to the classification of heart failure, updated the diagnostic process and recommended grade of chronic heart failure, and emphasized the cornerstone status of "new quadruple" treatment. The definition of end-stage heart failure has been added and the treatment of common complications of heart failure has been updated.
- heart failure /
- diagnostic process /
- recommendation level /
- guide interpretation

HTML全文

参考文献(12)

[1]	Wang H, Chai K, Du M, et al. Prevalence and incidence of heart failure among urban patients in china: a national population-based analysis[J]. Circ Heart Fail, 2021, 14(10): e008406. doi: 10.1161/CIRCHEARTFAILURE.121.008406
[2]	中华医学会心血管病学分会. 中国部分地区1980、1990、2000年慢性心力衰竭住院病例回顾性调查[J]. 中华心血管病杂志, 2002, 30(8): 450-454. doi: 10.3760/j:issn:0253-3758.2002.08.002
[3]	Zhang Y, Zhang J, Butler J, et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in china: results from the China Heart Failure (China-HF) Registry[J]. J Card Fail, 2017, 23(12): 868-875. doi: 10.1016/j.cardfail.2017.09.014
[4]	中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024, 52(3): 235-275. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYW201910003.htm
[5]	许顶立, 韩雅玲, 张抒扬. 与时代同行, 助力心力衰竭规范化诊治能力提升[J]. 中华心血管病杂志, 2024, 52(3): 231-234. https://xuewen.cnki.net/CCND-CCDJ202404260031.html
[6]	McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36): 3599-3726. doi: 10.1093/eurheartj/ehab368
[7]	Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure[J]. Circulation, 2022, 145(18): e895-e1032.
[8]	中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004
[9]	McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2023, 44(37): 3627-3639. doi: 10.1093/eurheartj/ehad195
[10]	Jhund PS, Kondo T, Butt JH, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER[J]. Nat Med, 2022, 28: 1956-1964. doi: 10.1038/s41591-022-01971-4
[11]	Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials[J]. Lancet, 2022, 400: 757-767. doi: 10.1016/S0140-6736(22)01429-5
[12]	de Boer RA, Hulot JS, Tocchetti CG, et al. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)[J]. Eur J Heart Fail, 2020, 22(12): 2272-2289.